8-K current report · filed Aug 11, 2026

Kyverna Therapeutics Inc (KYTX) 8-K Current Report: August 11, 2026

Item EX-99.1Item 2.02KYTX overview

Short answer

Kyverna Therapeutics Inc (KYTX) filed an 8-K current report with the SEC on August 11, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Kyverna reported financial results for the quarter ended June 30, 2026.

Kyverna Therapeutics Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Kyverna reported financial results for the quarter ended June 30, 2026
  • Business update and quarterly results available in Exhibit 99.1, relevant for pipeline and liquidity assessment

Item EX-99.1 · Exhibit EX-99.1

  • RMAT designation for miv-cel in non-active SPMS expands regulatory pathways and supports a broader neuroimmunology franchise
  • Rolling SPS BLA submission on track for Q4 2026, with potential priority review and 2027 commercial launch
  • Q2 net loss $38.3M, or $0.63 per share, versus $42.1M, or $0.97 per share, in Q2 2025
  • Cash, equivalents and marketable securities $199.4M at June 30, 2026, supporting operating runway into 2028 alongside loan availability
  • Key catalysts: KYSA-8 12-month data and gMG Phase 2 follow-up in Q3 2026, PMS data in Q4 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Kyverna Therapeutics Inc 8-K filings

Get the next KYTX 8-K as it lands

Follow KYTX for push alerts, or ask the research agent what this filing means.